HLA-DRB1 Specific Neutra™ Antibody Products

Struggling with inconsistent HLA-DRB1 targeting, prolonged drug development timelines, or unreliable assay reproducibility? Creative Biolabs' HLA-DRB1 specific Neutra™ antibody products leverage advanced recombinant engineering and epitope-specific validation to deliver high-affinity reagents that accelerate therapeutic discovery and diagnostic innovation.

Introduction to HLA-DRB1

Major Histocompatibility Complex, Class II, DR Beta 1 (HLA-DRB1) encodes the β-chain of the HLA-DR heterodimer, a critical component of MHC class II molecules. Expressed primarily on antigen-presenting cells, HLA-DRB1 facilitates extracellular antigen presentation to CD4+ T cells, thereby bridging innate and adaptive immunity. Polymorphisms in this gene profoundly influence immune response diversity, disease susceptibility, and transplant compatibility.

• Structural Insights

The HLA-DR complex comprises an α-chain and a β-chain (HLA-DRB1), forming a membrane-proximal antigen-binding groove. This groove accommodates peptide antigens derived from extracellular pathogens or self-proteins. X-ray crystallography reveals that allelic variations in HLA-DRB1 alter groove architecture, dictating peptide-binding specificity and T-cell receptor (TCR) engagement. Such structural plasticity underpins its central role in autoimmune pathogenesis and alloimmune responses.

• Immune Signaling Pathways

HLA-DRB1-mediated antigen presentation activates CD4⁺ T cells via TCR recognition, triggering downstream pathways such as NF-κB and MAPK. These pathways orchestrate cytokine production, T-helper cell differentiation (e.g., Th1/Th17), and B-cell antibody class-switching. Dysregulated HLA-DRB1-TCR interactions drive pathogenic autoreactive T-cell expansion, a hallmark of autoimmune disorders.

• Disease Associations

HLA-DRB1 alleles are strongly linked to autoimmune conditions. For instance, HLA-DRB1*04:01 and *01:01 correlate with rheumatoid arthritis (RA) susceptibility due to their affinity for citrullinated self-peptides. Similarly, HLA-DRB1*15:01 is a risk factor for multiple sclerosis, while specific alleles predispose to type 1 diabetes and systemic lupus erythematosus. In transplant medicine, donor-recipient HLA-DRB1 mismatching heightens graft rejection risks.

Fig.1 HLA-DRB1 interactions in the RA pathogenesis.1

Applications of Anti-HLA-DRB1 Neutralizing Antibodies

• Therapeutic Intervention in Autoimmunity

By selectively inhibiting pathogenic HLA-DRB1/peptide complexes, neutralizing antibodies reduce autoreactive T-cell infiltration in conditions like RA. Preclinical models demonstrate reduced joint inflammation and cartilage damage, supporting their potential as targeted biologics.

• Transplant Rejection Mitigation

In transplantation, neutralizing antibodies minimize alloimmune responses by blocking donor-specific HLA-DRB1 epitopes. This approach may reduce dependency on broad-spectrum immunosuppressants, lowering infection risks and improving graft survival.

• Diagnostic Biomarker Development

Quantifying HLA-DRB1 expression or allele-specific profiles aids in stratifying patients for personalized therapies. These antibodies enable precise detection in tissue samples or serum, enhancing prognostic accuracy for autoimmune flare-ups or transplant rejection.

• Vaccine Adjuvant Design

HLA-DRB1-targeting antibodies can modulate antigen presentation to skew immune responses toward tolerance or protective immunity, offering novel strategies for vaccine development against infectious or autoimmune triggers.

Our Anti-HLA-DRB1 Antibodies

Neutralizing antibodies against HLA-DRB1 offer transformative potential in modulating immune dysregulation. These antibodies block the antigen-binding groove or disrupt HLA-DR/TCR interactions, effectively dampening autoreactive T-cell activation. Creative Biolabs' anti-HLA-DRB1 antibodies are engineered for exceptional specificity, validated across ELISA, flow cytometry, and immunohistochemistry. Their high reproducibility and batch-to-batch consistency ensure reliable data generation in both therapeutic development and clinical diagnostics.

Creative Biolabs' HLA-DRB1 specific Neutra™ antibody products empower researchers and clinicians to overcome challenges in autoimmune therapy, transplant biology, and precision diagnostics. With rigorously validated performance and customizable formats, these tools are indispensable for advancing next-generation immunotherapies.

Contact our team today to explore tailored solutions for your HLA-DRB1 research needs.

REFERENCE

1. Wysocki, Tomasz, Marzena Olesińska, and Agnieszka Paradowska-Gorycka. "Current understanding of an emerging role of HLA-DRB1 gene in rheumatoid arthritis–from research to clinical practice." Cells 9.5 (2020): 1127. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/cells9051127IF: 5.2 Q2